news
War On Cancer 2018: targeted therapies in oncology
War On Cancer 2018 discussed how cancer treatments have evolved over the last few decades, and looked at the future of cancer therapies...
List view / Grid view
T cells
news
RIP1 kinase as a therapeutic target for pancreatic cancer
RIP1 has been shown to suppress the action of macrophages against the immune system and could be a potential therapeutic target for pancreatic cancer...
webinar
Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
news
Critical cancer immunity genes identified using genetic barcoding
Genetic barcoding using Pro-codes and CRISPR could be used to identify critical cancer immunity genes to aid future therapeutics...
news
Sugar specific molecules show promising results for new allergy vaccine
Using sugar molecules researchers have developed a new vaccine for hay fever that may reduce treatment times and increase the effectiveness of treatments...
news
Cancer cells hide to evade immunotherapy
Cancer cells have been found to evade immunotherapy by hiding behind human leukocyte antigens, with researchers identifying therapies to prevent relapse...
news
New understanding of T-cell receptor behaviour presents challenge for immunotherapies
Researchers in the U.S. have made a surprising discovery about the binding behaviour of a particular T-cell receptor, with complicated ramifications for immunotherapy developers.
article
Improved screening of therapeutic candidates using integrated fragment-based approaches
An integrated fragment-based approach, which reveals enzymatic inhibitors with potential therapeutic application, is the subject of this webinar.Taking place on 25 October 2018 at 3:00pm, the webinar is supported by NanoTemper Technologies.
article
Expert view: Multiplexed screens in biologics discovery
Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…
article
Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments
Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.
news
Matcha green tea kills cancer stem cells
Researchers have found that Matcha green tea has properties to combat breast cancer stem cells...
news
Autoimmune response drives vision loss in glaucoma
New research shows that immune cells developed from early exposure to bacteria contribute to vision loss in glaucoma patients...
news
Aggressive Th17 cells aggravate Parkinson’s disease
Researchers identify Parkinson's disease as a possible autoimmune disease...
news
New cancer immunotherapy shows promise in early tests
Researchers report that in preclinical models they can amplify macrophage immune responses against cancer using a self-assembling supramolecule...
news
New epigenetic drug against Mantle Cell Lymphoma
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)...
